Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 B, 2009, Pages 3668-3679

  Xiong, Hua ^a   Chen, Zhao Fei ^a   Liang, Qin Chuan ^b   Du, Wan ^a   Chen, Hui Min ^a   Su, Wen Yu ^a   Chen, Guo Qiang ^a   Han, Ze Guang ^c   Fang, Jing Yuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

Author keywords

Colorectal cancer; DNA methylation; JAK2 STAT3 STAT5 signalling pathway; Methyltransferase inhibitors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; JANUS KINASE 2; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT3 PROTEIN; STAT5 PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; COLORECTAL TUMOR; DNA METHYLATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; AZACITIDINE; CELL CYCLE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; G2 PHASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; JANUS KINASE 2; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 77449154609     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00661.x     Document Type: Article

References (54)

1. Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol. 2000, 249:135-64.
2. Momparler RL, Ayoub J. Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer. 2001, 34:S111-5.
3. Issa JP, Kantarjian H. Azacitidine. Nat Rev Drug Discov. 2005, S6-7.
4. Wijermans P, Lubbert M, Verhoef G. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000, 18:956-62.
5. Aparicio A, Eads CA, Leong LA. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol. 2003, 51:231-9.
6. Lyons J, Bayar E, Fine G. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies. Curr Opin Investig Drugs. 2003, 4:1442-50.
7. Issa JP, Garcia-Manero G, Giles FJ. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004, 103:1635-40.
8. Balch C, Yan P, Craft T. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther. 2005, 4:1505-14.
9. Niwa Y, Kanda H, Shikauchi Y. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene. 2005, 24:6406-17.
10. Lacronique V, Boureux A, Valle VD. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997, 278:1309-12.
11. Zhang F, Li C, Halfter H. Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene. 2003, 22:894-905.
12. Alvarez JV, Greulich H, Sellers WR. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res. 2006, 66:3162-8.
13. Shen Y, Devgan G, Darnell JE. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc Natl Acad Sci USA. 2001, 98:1543-8.
14. Mora LB, Buettner R, Seigne J. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002, 62:6659-66.
15. Ma XT, Wang S, Ye YJ. Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol. 2004, 10:1569-73.
16. Lassmann S, Schuster I, Walch A. STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation. J Clin Pathol. 2007, 60:173-9.
17. Lin Q, Lai R, Chirieac LR. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol. 2005, 167:969-80.
18. Xiong H, Zhang ZG, Tian XQ. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia. 2008, 10:287-97.
19. Han Y, Amin HM, Franko B. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood. 2006, 108:2796-803.
20. Chim CS, Fung TK, Cheung WC. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood. 2004, 103:4630-5.
21. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002, 8:945-54.
22. Khoury JD, Rassidakis GZ, Medeiros LJ. Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma. Blood. 2004, 104:1580-1.
23. Galm O, Yoshikawa H, Esteller M. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 2003, 101:2784-8.
24. He B, You L, Uematsu K. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA. 2003, 100:14133-8.
25. Wu C, Guan Q, Wang Y. SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J Cell Biochem. 2003, 90:1026-37.
26. Jegalian AG, Wu H. Regulation of Socs gene expression by the proto-oncoprotein GFI-1B: two routes for STAT5 target gene induction by erythropoietin. J Biol Chem. 2002, 277:2345-52.
27. Valentino L, Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol. 2006, 71:713-21.
28. Rakesh K, Agrawal DK. Controlling cytokine signaling by constitutive inhibitors. Biochem Pharmacol. 2005, 70:649-57.
29. Wu C, Sun M, Liu L. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene. 2003, 306:1-12.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25:402-8.
31. Lu R, Wang X, Chen ZF. Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells. J Biol Chem. 2007, 282:12249-59.
32. Morita Y, Naka T, Kawazoe Y. Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts. Proc Natl Acad Sci USA. 2000, 97:5405-10.
33. Wang YY, Zhou GB, Yin T. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA. 2005, 102:1104-9.
34. Hecht M, Papoutsi M, Tran HD. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. Cancer Res. 2004, 64:6109-18.
35. Luczak MW, Jagodzinski PP. The role of DNA methylation in cancer development. Folia Histochem Cytobiol. 2006, 44:143-54.
36. Hennessy BT, Garcia-Manero G, Kantarjian HM. DNA methylation in haematological malignancies: the role of decitabine. Expert Opin Investig Drugs. 2003, 12:1985-93.
37. Karpf AR, Moore BC, Ririe TO. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2′-deoxycytidine. Mol Pharmacol. 2001, 59:751-7.
38. Zhu WG, Hileman T, Ke Y. 5-aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem. 2004, 279:15161-6.
39. Fang JY, Chen YX, Lu J. Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116. Cell Res. 2004, 14:217-26.
40. Paling NR, Welham MJ. Role of the protein tyrosine phosphatase SHP-1 (Src homology phosphatase-1) in the regulation of interleukin-3-induced survival, proliferation and signalling. Biochem J. 2002, 368:885-94.
41. Kazansky AV, Kabotyanski EB, Wyszomierski SL. Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A. J Biol Chem. 1999, 274:22484-92.
42. Yoshikawa H, Matsubara K, Qian GS. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001, 28:29-35.
43. Sakai I, Takeuchi K, Yamauchi H. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood. 2002, 100:2926-31.
44. Cho-Vega JH, Rassidakis GZ, Amin HM. Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma. Leukemia. 2004, 18:1872-8.
45. Takeuchi K, Sakai I, Narumi H. Expression of SOCS3 mRNA in bone marrow cells from CML patients associated with cytogenetic response to IFN-alpha. Leuk Res. 2005, 29:173-8.
46. Brender C, Nielsen M, Kaltoft K. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood. 2001, 97:1056-62.
47. Mowen KA, Tang J, Zhu W. Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell. 2001, 104:731-41.
48. Lee DY, Teyssier C, Strahl BD. Role of protein methylation in regulation of transcription. Endocr Rev. 2005, 26:147-70.
49. Komyod W, Bauer UM, Heinrich PC. Are STATS arginine-methylated. J Biol Chem. 2005, 280:21700-5.
50. Schmelz K, Wagner M, Dorken B. 5-Aza-2′-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer. 2005, 114:683-95.
51. Han Y, Amin HM, Frantz C. Restoration of shp1 expression by 5-AZA-2′-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia. 2006, 20:1602-9.
52. Esteller M, Tortola S, Toyota M. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res. 2000, 60:129-33.
53. Fornaro M, Plescia J, Chheang S. Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem. 2003, 278:50402-11.
54. Kunnumakkara AB, Nair AS, Ahn KS. Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-kappaB activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis. Blood. 2007, 109:5112-21.